Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.05.2025 | Seed | $50M | - |
Mentions in press and media 5
| Date | Title | Description |
| 03.05.2025 | Avidicure's $50 Million Seed Round: A New Dawn in Cancer Treatment | Avidicure, a biotech company based in Amsterdam, has made waves in the oncology sector with its recent $50 million seed financing. This funding round, led by EQT Life Sciences, attracted notable players like Kurma Partners, BioGeneration Ve... |
| 02.05.2025 | Avidicure: $50 Million Seed Funding Closed For Developing New Multifunctional Antibody Modality | Avidicure, a biotechnology company creating an entirely new multifunctional antibody modality with broad applicability in oncology, announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation fr... |
| 24.04.2025 | Avidicure Raises $50M in Seed Financing | Avidicure, an Amsterdam, The Netherlands-based biotechnology company pioneering an entirely new multifunctional antibody modality with broad applicability in oncology, raised $50m in seed financing.
The round was led by EQT Life Sciences wi... |
| 10.10.2024 | Kurma Partners: First Closing Of €250 Million Biofund IV | Kurma Partners, an asset manager focused on improving human health, announced that it has raised EUR 140 million, completing the first closing of Biofund IV. By the final closing in 2025, Kurma aims to have raised a total of €250 million in... |
| - | Avidicure | - |
Reviews 0
